Alzheimer’s disease
Oct 23, 2026
Vascular Dementia Treatment Space: A Billion-Dollar Gap Waiting for Its First Approved Drug
Summary Vascular dementia is the second most common form of dementia after Alzheimer’s disease; however, no drug has been specifically approved for its treatment. In 2025, the total number of diagnosed prevalent cases of vascular dementia across the seven major markets was estimated at 3 million, with ...
Read More...
Jul 29, 2026
Neurotechnology: Transforming the Future of Brain Health and Human–Machine Interaction
For most of medical history, the brain has been the one organ we could describe but barely touch. Today, that's changing fast. A new wave of devices, implants, and algorithms is learning to listen to the brain's electrical language, and, increasingly, to talk back to it. This convergence of neuroscience, engineerin...
Read More...
Jul 24, 2026
Aβ-Protein Inhibitors in Alzheimer’s Disease: The Amyloid-Busting Arsenal Redefining Care
Summary Alzheimer’s disease treatment has shifted from symptomatic management to disease modification with the emergence of anti-amyloid beta (Aβ) inhibitors that target the root cause by clearing amyloid plaques. Biogen/Eisai’s LEQEMBI and Eli Lilly’s KISUNLA are currently the only Aβ-targeting therapies to...
Read More...
May 12, 2026
GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China; Artiva Announces Strong Early AlloNK® Results and FDA Alignment for Pivotal Rheumatoid Arthritis Trial in 2026; FDA Reviews LEQEMBI IQLIK Subcutaneous Starting Dose Under Priority Review Pathway; ParcelBio Announces Programmable mRNA Platform Amid $13M Capital Infusion; Entrada Therapeutics Reports Promising Topline Efficacy and Safety Results for ENTR-601-44 in Duchenne Muscular Dystrophy
GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China GSK plc revealed an exclusive strategic partnership with Sino Biopharmaceutical, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aimed at supporting the launch and expansion of bepir...
Read More...
May 11, 2026
Agitation in Alzheimer’s Disease Treatment Landscape: A New Dawn With AUVELITY’s Breakthrough Approval
Summary In the United States alone, agitation in Alzheimer’s disease represented nearly 5 million diagnosed cases, highlighting a considerable yet often underappreciated burden among patients. Brexpiprazole (REXULTI) marked a key milestone as the first FDA-approved therapy specifically indicated for agitatio...
Read More...
May 05, 2026
UCB to Acquire Candid Therapeutics; Pfizer’s ELREXFIO Sets New Benchmark in PFS for Hard-to-Treat Multiple Myeloma Patients; Axsome Therapeutics Wins FDA Approval for AUVELITY to Address Alzheimer’s Agitation; FDA Advisory Panel Backs Truqap for PTEN-Deficient mHSPC; Bepirovirsen Receives FDA Priority Review Alongside Breakthrough Therapy Tag
UCB Bets on Candid Therapeutics to Boost Immunology Pipeline with T-cell Engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics, strengthening its immunology pipeline and advancing its capabilities in next-generation biologics, particularly T-cell engagers (TCEs). The deal aligns wit...
Read More...
Jan 06, 2026
Zenas BioPharma’s Obexelimab Delivers Positive Phase 3 Results in IgG4-RD; Sanofi Secures US Priority Review for Tzield in Pediatric Stage 2 Type 1 Diabetes; Axsome’s AXS-05 sNDA Accepted by FDA with Priority Review for Alzheimer’s Agitation; Vanda’s NEREUS Receives FDA Approval; Omeros’ YARTEMLEA Sets Milestone as First Approved TA-TMA Therapy
Zenas BioPharma Announces Successful Phase 3 INDIGO Study of Obexelimab in IgG4-RD Zenas BioPharma has announced positive top-line results from its pivotal Phase 3 INDIGO clinical trial evaluating obexelimab for the treatment of IgG4-Related Disease (IgG4-RD). IgG4-RD is a rare, systemic, chronic fibroinflammato...
Read More...
Dec 17, 2025
The Automated Eye: How AI-Driven Diagnostics are Reshaping the Future of Medical Imaging
Artificial intelligence (AI) has rapidly emerged as a transformative force in medical imaging, revolutionizing disease detection, diagnosis, and monitoring. From radiology to pathology, AI algorithms are enhancing image interpretation, improving diagnostic accuracy, and streamlining clinical workflows across health...
Read More...
Nov 25, 2025
Novartis Secures FDA Approval for ITVISMA; Kelun-Biotech’s Phase III Study Shows Sac-TMT + Keytruda Achieves Primary Endpoint in First-Line PD-L1-Positive NSCLC; Evoke Phase 3 Trials Failed to Show a Statistically Significant Impact on Alzheimer’s Disease Progression; Sangamo Therapeutics Gets FDA Nod for Rolling BLA Submission of ST-920 in Fabry Disease; Bayer’s HYRNUO Receives FDA Accelerated Approval for Previously Treated HER2-mutant NSCLC
Novartis Secures FDA Approval of ITVISMA for Children Two Years and Older, Teens, and Adults with Spinal Muscular Atrophy (SMA) Novartis has announced a significant expansion in the treatment landscape for Spinal Muscular Atrophy (SMA) with the FDA approval of ITVISMA (onasemnogene abeparvovec-brve). This one-ti...
Read More...
Oct 28, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Wireless brain sensors are emerging as a transformative technology in neuroscience and healthcare, offering a new level of precision, comfort, and real-time monitoring for patients with neurological conditions. Unlike traditional wired sensors that limit mobility and can cause discomfort, wireless brain sensors use...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
